1623 Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

1623 Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,756	Closed	-$122K	–	86
2021 Q1	$122K	Buy	+5,756	New	+$167K	0.05%	66

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

1623 Capital's RYTM Position: Q2 2021 in Review

1623 Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2021, closing a stake of 5,756 shares — an estimated $122K sold.

1623 Capital first reported a position in RYTM in Q1 2021 and held it in 1 quarter. The position peaked at $122K in Q1 2021. 105 funds tracked by Wall St. Rank hold RYTM as of Q2 2021.

1623 Capital reported no remaining Rhythm Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
1623 Capital sold 5,756 Rhythm Pharmaceuticals shares in Q2 2021, an estimated $122K.
1623 Capital first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 1 quarter.
1623 Capital's Rhythm Pharmaceuticals position peaked at $122K in Q1 2021.
105 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2021.

Based on 1623 Capital's 13F filing for Q2 2021, filed 13 Aug 2021.